On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) Featured in Mizuho Securities Research Report

Company: Biohaven Pharmaceutical Holding Company (BHVN)
Category: Analyst Alerts

Biohaven Pharmaceutical Holding Company (NYSE: BHVN) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We are updating our Biohaven model after 2Q20 earnings, accounting for the results and the recently announced financing agreement with Royalty Pharma (RPRX; Not Covered) and term loan with Sixth Street to support Nurtec ODT’s ongoing launch and the development of zavegepant. We believe these agreements provide attractive forms of financing that obviate the near-term need for additional capital raise, while allowing Biohaven to compete in the migraine market. Nurtec’s uptake continues to impress us, and we expect payer reimbursement and discounts to improve as the product becomes established and patient promotional programs expire. We maintain our Buy rating but lower our PT to $82 (from $85) mainly due to increased assumptions around SG&A.”

To request access to the full report, visit http://nnw.fm/SaZ9d

About Biohaven Pharmaceutical Holding Company Ltd.

Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven’s neuroinnovation portfolio includes FDA-approved NURTEC(TM) ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer’s disease, and spinocerebellar ataxia; and MPO inhibition for multiple system atrophy and amyotrophic lateral sclerosis. For more information, visit the company’s website at www.BiohavenPharma.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217